Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

NCT02568683 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Entospletinib
DRUG: Vincristine

Sponsor

Gilead Sciences